Following Beijing's notification that the Pu Shi Medical Laboratory was suspected of obstructing the prevention and control of infectious diseases, on the afternoon of May 27, a press conference on Beijing's epidemic prevention and control work reported that Beijing Jinzhun Medical Laboratory Co., Ltd. There are cases of suspected illegal crimes.
According to the report, since April 25 this year, in order to seek illegal economic benefits, the Beijing Jinzhun Medical Laboratory has illegally mixed the nucleic acid samples of "5 mixed with 1" and "10 mixed with 1" collected in multiple areas, using the method of multi-tube mixed inspection. For testing, artificially dilute the sample, which affects the accuracy of the test results and is suspected of obstructing the prevention and treatment of infectious diseases.
According to a report on the official website of the Beijing Municipal Health Commission, the Haidian District Health Commission has been ordered to immediately suspend the practice of Beijing Jinzhun Medicine, stop undertaking the nucleic acid testing business of the new coronavirus, and conduct investigation and evidence collection.
At present, the company has been put on file for investigation, and 17 people in the company have been taken criminal compulsory measures by Haidian police according to law, and the case is under further investigation.
Li Ang, deputy director and spokesperson of the Beijing Municipal Health Commission, said at the press conference that the nucleic acid testing institutions involved will be dealt with seriously and will not be tolerated. Violation issues.
According to a report on the quality of nucleic acid testing institutions issued by the Beijing Municipal Health and Health Commission on May 27, Beijing will carry out on-site inspections of nucleic acid testing institutions across the city without leaving any dead ends.
Further strengthen the quality supervision of nucleic acid testing laboratories, improve work processes, and strengthen process audit checks.
Jinzhun Medical has been stopped from undertaking the new coronavirus nucleic acid testing business after it has stated that it is strict in quality management
According to the Beijing Municipal Health and Health Commission's report on May 27, Beijing Jinzhun Medical Laboratory has violated regulations to conduct 3-tube mixed-tube testing on multiple samples in its work since April 25.
In violation of regulations, the nucleic acid samples of "5 mixed with 1" and "10 mixed with 1" collected in multiple areas are tested by multi-tube mixed testing, and the samples are artificially diluted.
The artificial dilution of the sample will affect the accuracy of the test results. Because of the crime of obstructing the prevention and treatment of infectious diseases, the company has been filed for investigation. The legal representative Wang Moumou (male, 43 years old) and other 17 people have been taken criminal compulsory measures by the Haidian police according to law. , the case is under further investigation.
According to a report on the official website of the Beijing Municipal Health Commission, the Haidian District Health Commission has been ordered to immediately suspend the practice of Beijing Jinzhun Medicine, stop undertaking the nucleic acid testing business of the new coronavirus, and conduct investigation and evidence collection.
A reporter from Shell Finance noticed that on June 20, 2020, Jinzhun Gene passed the review of the expert group of the Beijing Municipal Health Commission and began to undertake the task of nucleic acid detection of the new coronavirus.
Jinzhun Gene, which had nearly 200 professional and technical personnel at that time, also said that Beijing Jinzhun Medical Laboratory will strictly follow the relevant regulations of the state and the city on carrying out new coronavirus nucleic acid detection, biosafety protection, and biological sample resource management, adhering to the The concept of "strict quality management, convenient testing process, and professional testing services" has contributed to the fight against the epidemic.
The reporter saw on the official website of the Beijing Municipal Health Commission that in the list of qualified institutions for the examination of the new coronavirus nucleic acid detection medical laboratory updated in Beijing in February, March and April, the Beijing Jinzhun Medical Laboratory in Haidian District was in it.
It also has business in Harbin. In which areas has Jinzhun Medical provided nucleic acid testing services?
So, which areas did Jinzhun Medical in question provide nucleic acid testing services?
Who are the shareholders behind it?
What business are there?
A reporter from Shell Finance noticed that as of March 24, Beijing Jinzhun Medicine was also located in Cuihu Science and Technology Park in Zhongguancun, Haidian District, Beiqijia Town, Changping District, Wanda Plaza in Tongzhou District, Laoshan Urban Leisure Park in Shijingshan District, Daxing District, etc. There are 11 sampling points in the ground.
On April 9, Beijing Jinzhun Medical Laboratory also adjusted the price of nucleic acid testing for the new coronavirus, and the single-person, single-tube testing fee for external sampling point services was adjusted to 24.9 yuan per person.
The group sampling service costs 24.9 yuan per person for apheresis testing, and 5.9 yuan per person for mixed sampling and testing.
On May 27, the reporter saw through the platform that there were only two nucleic acid sampling sites left by Jinzhun Medicine, both located in Dougezhuang Township, Chaoyang District.
The reporter dialed the consulting mobile phone number of Jinzhun Medical Laboratory, but the phone showed that it could not be connected.
Through equity traceability, the reporter found that Beijing Jinzhun Medical Laboratory is a wholly-owned subsidiary of Beijing Jinzhun Gene Technology Co., Ltd., and Beijing Jinzhun Gene is 100% owned by Harbin Precision Gene Technology Co., Ltd.
According to the official information released by Harbin Jinzhun Medical Laboratory, Harbin Precision Gene has several branches in Beijing, Shenzhen and Shanghai, whose business covers reproductive health, tumor screening, individualized medication guidance, single-gene genetic diseases, scientific research services, etc. an area.
The reporter noticed that in the early stage of the prevention and control of the new crown epidemic in 2020, Harbin Jinzhun Medical Laboratory has also become one of the medical testing institutions in Harbin.
The actual controller of Harbin Precision Gene is Wang Xuegang, who directly holds about 34% of the shares, and Beijing Qianhai Precision Gene, which is indirectly controlled, holds 9.25% of the shares of Harbin Jinzhun Gene.
The actual controller is a director of Baipsis, and has been taken criminal compulsory measures
Wang Xuegang himself is still a director of the listed company Baipsis.
On the evening of May 27, Baipsis issued an announcement stating that due to the suspected illegal and criminal behavior of Jin Zhun Medicine, the Beijing police opened a case for Jin Zhun Medicine, and Wang Xuegang, the legal representative of Jin Zhun Medicine, and others were taken criminal compulsory measures in accordance with the law. under investigation.
The announcement pointed out that director Wang Xuegang is an external director of the company, does not hold other positions other than directors, and does not participate in the daily operation and management of the company.
At present, the company's operation is normal, and this matter has no impact on the company's production and operation, financial status and solvency.
According to the information previously disclosed by the company, Wang Xuegang was born in 1978 and graduated from the Bioinformatics major of Overs University in Denmark with a master's degree.
He joined Beijing Huada Gene Research Center in July 1999. From October 2009 to March 2015, he served as the vice president of Shenzhen Huada Gene Technology Co., Ltd.; since May 2015, he has been the chairman of Harbin Precision Gene Technology Co., Ltd.
In addition to COVID-19 testing, companies such as Harbin Precision Gene also have large-scale other genetic testing services.
According to the company's data, Harbin Precision Gene is the main company, and there are 11 member companies, which are distributed in Harbin, Beijing, Shanghai, Hebei and Shenzhen.
According to the official website of Jinzhun Gene, "it has cooperated with 80+ cities, 600+ hospitals, 2000+ clinical experts and physicians to provide genetic testing services for 10W+ subjects".
The reporter noticed that Wang Xuegang was also a director of a Hangzhou Kechang Technology Consulting Co., Ltd.
In addition, Wang Xuegang also held 60% of Ningbo Anke Biotechnology Co., Ltd. and 57% of Ningbo Ankepton Biotechnology Co., Ltd., both of which were cancelled in 2019.
According to the company's data, Wang Xuegang also pledged the equity of Harbin Precision Gene Technology Co., Ltd. to Harbin Venture Capital Group Co., Ltd. for 5.834 million yuan in 2020.
The equity relationship behind Harbin Precision Gene is equally complicated, with listed companies appearing.
The data shows that the largest shareholder of Harbin Precision Gene is Wang Xuegang, and the second largest shareholder is Harbin Fudeheng Venture Capital Enterprise.
At present, Harbin Venture Capital Group Co., Ltd., which holds 20% of Harbin Fudehengchuang, is behind Harbin's local state-owned assets.
In addition, Beijing Chunfeng Bairun Equity Investment Partnership holds about 4.6% of the shares of Harbin Precision Gene. Behind the company, listed company Hainan Haiyao holds 35.36% and Ningbo Aux, a subsidiary of listed company Samsung Medical, holds 35.36%.
Beijing News Shell Finance reporter Li Yunqi